TAIPEI and SAN DIEGO, Dec. 10, 2025 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company developing first-in-class therapies for difficult-to-treat cancers, today announced a clinical supply agreement with BeOne Medicines, a global oncology…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
